Terms & Conditions
Research basis for DHA-Core claims.
This page summarizes the scientific, regulatory, and quality-control basis behind the claims used on this website. It is not medical advice and does not replace guidance from a healthcare professional.
Permitted health claims
Claims are limited to authorized DHA/EPA wording.
DHA-Core uses claim language aligned with EU-authorized DHA and EPA claim territory. The website may state that DHA contributes to the maintenance of normal brain function and normal vision when the daily intake condition of 250 mg DHA is met. Each softgel is specified to provide 300 mg DHA and 150 mg EPA. EPA and DHA may contribute to the normal function of the heart when the required combined intake is met.
- DHA contributes to the maintenance of normal brain function at a daily intake of 250 mg DHA.
- DHA contributes to the maintenance of normal vision at a daily intake of 250 mg DHA.
- EPA and DHA contribute to the normal function of the heart when the required combined intake is met.
Ingredient status
Schizochytrium sp. oil has an established EU regulatory path.
The research identifies Schizochytrium sp. microalgae oil as the appropriate launch ingredient because forms of Schizochytrium sp. oil are included in the EU Union List of Novel Foods. The research references Commission Implementing Regulation (EU) 2018/1032, Commission Implementing Regulation (EU) 2022/1365, and later specification updates for Schizochytrium sp. oil rich in DHA and EPA.
The EFSA NDA Panel has also evaluated Schizochytrium-derived oil for food supplement use. This supports the decision to focus the first DHA-Core product on algae Omega-3 softgels.
Source rationale
Algae are the direct source of marine DHA.
The website's algae-first sourcing claim is based on the biological role of microalgae in the marine Omega-3 chain. Fish oil provides DHA and EPA because fish accumulate these fatty acids through the food chain. DHA-Core uses microalgae oil directly, supporting the fish-free, vegan positioning without relying on fish as the delivery route.
Quality conditions
Oxidation control is treated as a product requirement.
The research identifies oxidation control as central for Omega-3 quality. DHA-Core's quality framework is built around supplier documentation, Certificate of Analysis review, peroxide value, anisidine value, TOTOX monitoring, protective packaging, and softgel encapsulation.
- Peroxide value (PV) tracks primary oxidation and freshness.
- Anisidine value (AV) tracks secondary oxidation and rancidity markers.
- TOTOX combines PV and AV to monitor total oxidation status.
- Softgel encapsulation and antioxidant-support ingredients help protect the oil during storage and daily use.
Use conditions
Food supplement boundaries apply.
DHA-Core is a food supplement, not a medicine. It is not intended to diagnose, treat, cure, or prevent disease. Food supplements should not be used as a substitute for a varied diet. Do not exceed the recommended daily dose. Keep out of reach of young children. If pregnant, breastfeeding, or on blood-thinning medication, consult a healthcare professional before use.
Privacy and GDPR
How DHA-Core handles form data.
When you submit a form on this website, DHA-Core collects the personal data you choose to provide, such as your name, email address, country, message, and stated interest. We use this data only to respond to your request, manage launch updates, handle pre-launch interest, and keep a reasonable record of communication.
Form submissions are processed through Netlify Forms and may be sent to the DHA-Core contact email for follow-up. We do not sell your personal data. You can ask us to access, correct, or delete your personal data by contacting customer@dha-core.com.
This consent notice refers to Regulation (EU) 2016/679, the General Data Protection Regulation. You can read the official EU text here: Regulation (EU) 2016/679.
References used
Core research sources.
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (2021). Safety of oil from Schizochytrium limacinum (strain FCC-3204) for use in food supplements. EFSA Journal, 19(1), e06345.
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (2023). Safety of oil from Schizochytrium sp. (strain CABIO-A-2) for use in infant and follow-on formula. EFSA Journal, 21(12), e8415.
- European Commission (2018). Commission Implementing Regulation (EU) 2018/1032 authorising extension of use of oil from Schizochytrium sp. as a novel food.
- European Commission (2022). Commission Implementing Regulation (EU) 2022/1365 amending conditions of use for Schizochytrium sp. oil rich in DHA and EPA.
- DHA-Core internal research presentation (2026). Product direction, regulatory landscape, quality targets, and EFSA-approved health claim summary.
